AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36064731 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group with access to the wristband solution and standard care
Number of subjects: 170
Study 36064731 — intervention group
Group type: COMPARATOR
Intervention: Delayed group with access to standard care only
Number of subjects: 170
Study 33075546 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent exudative nAMD developed in 73 eyes (9.6%) of the incident GA cohort over a mean follow-up of 2.3 years.
Number of subjects: 1213
Study 33075546 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent exudative nAMD developed in 63 eyes (13.8%) of the prevalent GA cohort over a mean follow-up of 4.1 years.
Number of subjects: 1213
Study 32960242 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative pressure wound therapy (n = 816, median duration 4 days)
Number of subjects: 1624
Study 32960242 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing (n = 808)
Number of subjects: 1624
Study 32960242 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative pressure wound therapy
Number of subjects: 1624
Study 32960242 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 1624
Study 37081533 — intervention group
Group type: EXPERIMENTAL
Intervention: check‐up 45+
Number of subjects: 1654
Study 37081533 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1654
Study 33340964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesticide training program
Number of subjects: 0
Study 33340964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32768635 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive regulation (enhancement and suppression abilities)
Number of subjects: 247
Study 32768635 — intervention group
Group type: COMPARATOR
Intervention: Peer exclusion (manipulated through a Cyberball game)
Number of subjects: 247
Study 35677636 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound lactic acid bacteria capsules combined with escitalopram
Number of subjects: 60
Study 35677636 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 60
Study 32910152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 1943
Study 32910152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1943
Study 35465007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐0.7 μg/kg/h)
Number of subjects: 36
Study 35465007 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36
Study 34215275 — intervention group
Group type: EXPERIMENTAL
Intervention: EIRA intervention (multiple health behaviour change intervention)
Number of subjects: 3062
Study 34215275 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3062
Study 34215275 — intervention group
Group type: EXPERIMENTAL
Intervention: EIRA intervention
Number of subjects: 3062
Study 35538431 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day resveratrol
Number of subjects: 76
Study 35538431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 33280541 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial distance manipulation
Number of subjects: 205
Study 36353267 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroaspis plp10
Number of subjects: 61
Study 36353267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32532601 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homoeopathic treatment (11 medicines prescribed in potencies from 6C to 1M)
Number of subjects: 84
Study 32532601 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 84
Study 32039984 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage video instruction before observation
Number of subjects: 98
Study 32039984 — intervention group
Group type: COMPARATOR
Intervention: Infant massage video instruction after observation
Number of subjects: 98
Study 35915473 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (individually-tailored, text-message and website-delivered, Spanish-language intervention)
Number of subjects: 0
Study 35915473 — intervention group
Group type: COMPARATOR
Intervention: Original Intervention (web-based Pasos Hacia La Salud Intervention)
Number of subjects: 0
Study 35915473 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Number of subjects: 0
Study 35915473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study arms
Number of subjects: 0
Study 34687634 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily for 12 months
Number of subjects: 211
Study 34687634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 32657437 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Niacinamide (Nam)
Number of subjects: 40
Study 32657437 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study 34741749 — intervention group
Group type: EXPERIMENTAL
Intervention: US-based radiomics model
Number of subjects: 548
Study 34741749 — intervention group
Group type: EXPERIMENTAL
Intervention: Final nomogram
Number of subjects: 548
Study 34741749 — intervention group
Group type: COMPARATOR
Intervention: Clinical and conventional US model
Number of subjects: 548
Study 34741749 — intervention group
Group type: EXPERIMENTAL
Intervention: Final nomogram in contrast-enhanced US
Number of subjects: 548
Study 33483435 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine, CPAP, and surfactant via the LISA method
Number of subjects: 180
Study 33483435 — intervention group
Group type: COMPARATOR
Intervention: Caffeine and CPAP alone
Number of subjects: 180
Study 33301009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 mL/kg of concentrated beetroot juice containing 200 µmol/kg of nitrate
Number of subjects: 9
Study 33301009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 33301009 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 mL/kg of concentrated beetroot juice containing 400 µmol/kg of nitrate
Number of subjects: 9
Study 33301009 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of nitrate
Number of subjects: 9
Study 32484441 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook educational program (n=40)
Number of subjects: 80
Study 32484441 — intervention group
Group type: COMPARATOR
Intervention: Email educational program (n=40)
Number of subjects: 80
Study 35643988 — intervention group
Group type: EXPERIMENTAL
Intervention: Three treatments with CPM‐HA20G (total 3 ml per side)
Number of subjects: 15
Study 35643988 — intervention group
Group type: EXPERIMENTAL
Intervention: One treatment with CPM‐HA20G (total 1.5 ml per side)
Number of subjects: 15
Study 32978705 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill slip‐perturbation training (Tt)
Number of subjects: 152
Study 32687763 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 32687763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35718807 — intervention group
Group type: EXPERIMENTAL
Intervention: 940 nm diode laser (1 W, continuous-wave)
Number of subjects: 17
Study 35718807 — intervention group
Group type: EXPERIMENTAL
Intervention: 2780 nm Er,Cr:YSGG laser (1.5 W, 30 Hz)
Number of subjects: 17
Study 35718807 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 17
Study 33745609 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (500 mg daily for 8 weeks)
Number of subjects: 46
Study 33745609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34848344 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]‐NaF PET/MR
Number of subjects: 39
Study 34848344 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) including clinical examination and conventional MRI
Number of subjects: 39
Study 34848344 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration of all facet joints being PET/MR‐positive
Number of subjects: 39
Study 33044240 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal drugs in high-risk critically ill patients without microbiologic documentation of Candida infection
Number of subjects: 0
Study 33044240 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine universal screening for complications in candidemic patients
Number of subjects: 0
Study 33044240 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of echinocandins for treating invasive candidiasis
Number of subjects: 0
Study 33044240 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of fungal biomarkers for early initiation or interruption of antifungal therapy
Number of subjects: 0
Study 33044240 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted screening of eye infection and endocarditis with fungal biomarkers
Number of subjects: 0
Study 35871331 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeedCourt® system
Number of subjects: 39
Study 35871331 — intervention group
Group type: COMPARATOR
Intervention: Fitfor100 program
Number of subjects: 39
Study 34560265 — intervention group
Group type: EXPERIMENTAL
Intervention: SaMBA-COPD intervention with lay health coaches, including referral to a pharmacist for antibiotic and oral steroid rescue packs and support for a structured home exercise routine.
Number of subjects: 58
Study 34560265 — intervention group
Group type: COMPARATOR
Intervention: COPD education control
Number of subjects: 58
Study 33637618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of conbercept (0.25 mg)
Number of subjects: 30
Study 33637618 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of ranibizumab (0.25 mg)
Number of subjects: 30
Study 34540595 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention (8 modules based on cognitive behavioral therapy)
Number of subjects: 0
Study 34540595 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy (active control group)
Number of subjects: 0
Study 34540595 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention
Number of subjects: 0
Study 32593487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tantalum acetabular component
Number of subjects: 66
Study 32593487 — intervention group
Group type: COMPARATOR
Intervention: Titanium acetabular component with ancillary screw fixation
Number of subjects: 66
Study 32593487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tantalum and Titanium)
Number of subjects: 66
Study 35758093 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day aspirin (ASA)
Number of subjects: 274
Study 35758093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 32345787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal CO2 laser treatment
Number of subjects: 88
Study 32345787 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 88
Study 33527137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 312
Study 33527137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 32106176 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized Resistance Training (PRD)
Number of subjects: 49
Study 32106176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized Resistance Training (NPRD)
Number of subjects: 49
Study 32106176 — intervention group
Group type: COMPARATOR
Intervention: No-Resistance Training (NRT)
Number of subjects: 49
Study 33970455 — intervention group
Group type: EXPERIMENTAL
Intervention: Centhaquine (0.01 mg/kg in 100 ml normal saline infusion over 1 h)
Number of subjects: 50
Study 33970455 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml normal saline infusion over 1 h)
Number of subjects: 50
Study 32546239 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment for 6 months
Number of subjects: 50
Study 32546239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 36351635 — intervention group
Group type: EXPERIMENTAL
Intervention: Video calls with dispatchers
Number of subjects: 70
Study 36351635 — intervention group
Group type: COMPARATOR
Intervention: Voice calls with dispatchers
Number of subjects: 70
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles using ORs in AJPH
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles using ORs in NEJM
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles using ORs in PLOS One
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles using ORs in JAMA
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Any articles reporting effect size
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles reporting any effect size
Number of subjects: 6124
Study 33303479 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles with correct effect size interpretation
Number of subjects: 6124
Study 35964235 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM retainers
Number of subjects: 181
Study 35964235 — intervention group
Group type: COMPARATOR
Intervention: Conventional retainers
Number of subjects: 181
Study 35964235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study 33931900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliadin-protected SOD (GP-SOD; 1 g/day for 12 weeks followed by 0.5 g/day for 12 weeks) + NB-UVB
Number of subjects: 50
Study 33931900 — intervention group
Group type: COMPARATOR
Intervention: Placebo + NB-UVB
Number of subjects: 50
Study 32065006 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray (nabiximols)
Number of subjects: 0
Study 32065006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32958502 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HRV-BF with resonant breathing (n=25)
Number of subjects: 50
Study 32958502 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 33306873 — intervention group
Group type: EXPERIMENTAL
Intervention: Drachman criteria
Number of subjects: 237
Study 33306873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantegazza criteria
Number of subjects: 237
Study 33306873 — intervention group
Group type: EXPERIMENTAL
Intervention: Suh criteria
Number of subjects: 237
Study 33306873 — intervention group
Group type: EXPERIMENTAL
Intervention: International Consensus Guideline (ICG)
Number of subjects: 237
Study 33306873 — intervention group
Group type: EXPERIMENTAL
Intervention: REGAIN criteria
Number of subjects: 237
Study 35723751 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 36
Study 35723751 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide + 2% chlorhexidine-gel (Ca(OH)2 + 2% CHX-gel)
Number of subjects: 36
Study 35723751 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide + saline solution (Ca(OH)2 + SSL)
Number of subjects: 36
Study 34426469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph Node Ratio (LNR)
Number of subjects: 1038
Study 34426469 — intervention group
Group type: EXPERIMENTAL
Intervention: Log Odds of Positive Lymph Nodes (LODDS)
Number of subjects: 1038
Study 34426469 — intervention group
Group type: COMPARATOR
Intervention: Traditional N staging method
Number of subjects: 1038
Study 32741790 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation robot training (RRT)
Number of subjects: 40
Study 32741790 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy
Number of subjects: 40
Study 35395555 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nut consumption (67 g/day providing 25.5 g protein and 174 mg isoflavones)
Number of subjects: 23
Study 35395555 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy nut consumption (67 g/day)
Number of subjects: 23
Study 35395555 — intervention group
Group type: COMPARATOR
Intervention: Control (no nuts)
Number of subjects: 23
Study 32147256 — intervention group
Group type: COMPARATOR
Intervention: Milk replacer without fatty acid supplementation and without access to a dry teat (control)
Number of subjects: 240
Study 32147256 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk replacer with fatty acid supplementation (NeoTec5g, Provimi, Brookville, OH) and without access to a dry teat (FAS)
Number of subjects: 240
Study 32147256 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk replacer without fatty acid supplementation and with access to a dry teat (TT)
Number of subjects: 240
Study 32147256 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk replacer with fatty acid supplementation and with access to a dry teat (FAS+TT)
Number of subjects: 240
Study 32147256 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (FAS, TT, FAS+TT)
Number of subjects: 240
Study 34311336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibwife moving mattress used for 10 minutes
Number of subjects: 50
Study 34311336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibwife moving mattress used for 20 minutes
Number of subjects: 50
Study 34311336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibwife moving mattress used for 30 minutes
Number of subjects: 50
Study 34311336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibwife moving mattress overall
Number of subjects: 50
Study 35164857 — intervention group
Group type: EXPERIMENTAL
Intervention: Break Free smoking cessation program
Number of subjects: 510
Study 33415523 — intervention group
Group type: EXPERIMENTAL
Intervention: E group (with Humulus lupulus)
Number of subjects: 252
Study 33415523 — intervention group
Group type: EXPERIMENTAL
Intervention: E and D groups (with Humulus lupulus)
Number of subjects: 252
Study 33415523 — intervention group
Group type: EXPERIMENTAL
Intervention: W-D, N-D, W-E, and N-E groups (with different molting methods)
Number of subjects: 252
Study 33415523 — intervention group
Group type: COMPARATOR
Intervention: Molting programs (various groups)
Number of subjects: 252
Study 33415523 — intervention group
Group type: COMPARATOR
Intervention: Post-molting period (after applying molting methods)
Number of subjects: 252
Study 33415523 — intervention group
Group type: COMPARATOR
Intervention: White button mushroom residual (for forced molting)
Number of subjects: 252
Study 33415523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop (in second laying cycle)
Number of subjects: 252
Study 32174033 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT) in conjunction with carpal tunnel release surgery (CTRS)
Number of subjects: 35
Study 32174033 — intervention group
Group type: COMPARATOR
Intervention: Carpal tunnel release surgery (CTRS) alone
Number of subjects: 35
Study 36038277 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed medicolegal training
Number of subjects: 1060
Study 34517775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (taking ?5 medications)
Number of subjects: 168
Study 34517775 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medication (PIM) use
Number of subjects: 168
Study 34517775 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic score ?1
Number of subjects: 168
Study 34517775 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between number of medications and number of PIMs
Number of subjects: 168
Study 34517775 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between number of medications and anticholinergic score
Number of subjects: 168
Study 34268888 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume subcutaneous injection (1, 8, and 20 cP viscosities, up to 10ml in abdomen and 5ml in thigh)
Number of subjects: 32
Study 34268888 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume subcutaneous injection
Number of subjects: 32
Study 34790138 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine (72 mg/d)
Number of subjects: 89
Study 34790138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 35835135 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus trabectedin (60 mg/m2 doxorubicin and 1.1 mg/m2 trabectedin)
Number of subjects: 150
Study 35835135 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone (75 mg/m2)
Number of subjects: 150
Study 35835135 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus trabectedin
Number of subjects: 150
Study 35835135 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 150
Study 33749741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 8‐mg dose of dexamethasone
Number of subjects: 302
Study 33749741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 33090380 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐Ser treatment for 12 months
Number of subjects: 51
Study 33090380 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 months
Number of subjects: 51
Study 35970815 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (n=203)
Number of subjects: 408
Study 35970815 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment (n=360)
Number of subjects: 408
Study 35970815 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin treatment (specific numbers not provided)
Number of subjects: 408
Study 35970815 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antibiotic prophylaxis at discharge (specific numbers not provided)
Number of subjects: 408
Study 34425901 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 120
Study 34425901 — intervention group
Group type: COMPARATOR
Intervention: Tell-Show-Do (TSD)
Number of subjects: 120
Study 32319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa inhalation powder 84 mg
Number of subjects: 0
Study 32319076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34754306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% capsaicin paste (EP group)
Number of subjects: 40
Study 34754306 — intervention group
Group type: COMPARATOR
Intervention: Water (Control group)
Number of subjects: 40